These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 1465911)

  • 1. Six-year experience with a triple drug protocol in renal transplantation: analysis of risk factors.
    Pallardó LM; Sánchez P; Sánchez J; García J; Orero E; Beneyto I; Cruz JM
    Transplant Proc; 1992 Dec; 24(6):2714-5. PubMed ID: 1465911
    [No Abstract]   [Full Text] [Related]  

  • 2. Repeated HLA mismatch in multiple kidney transplantation: preliminary results of 146 retransplantations in the cyclosporine era.
    Gnant MF; Sautner T; Rosenmayr A; Muehlbacher F
    Transplant Proc; 1992 Dec; 24(6):2466-8. PubMed ID: 1465833
    [No Abstract]   [Full Text] [Related]  

  • 3. Enhanced renal graft survival in HLA-A mismatched transplants.
    Bućin D; Ekberg H; Lindholm A; Persson H; Tufvesson G; Albrechtsen D
    Transplant Proc; 1992 Dec; 24(6):2473-4. PubMed ID: 1465837
    [No Abstract]   [Full Text] [Related]  

  • 4. Repeated mismatches may not impair survival of renal regrafts in recipients with 0% to 50% panel reactive antibodies.
    Mjörnstedt L; Konar J; Skarp I; Olausson M; Sandberg L; Tufvesson G
    Transplant Proc; 1992 Dec; 24(6):2469. PubMed ID: 1465834
    [No Abstract]   [Full Text] [Related]  

  • 5. Quality of serological donor HLA typing: analysis of graft survival by HLA in renal transplantation recipients treated with cyclosporine.
    Thorogood J; Schreuder GM; Persijn GG; van Rood JJ
    Transplant Proc; 1992 Dec; 24(6):2485-7. PubMed ID: 1465839
    [No Abstract]   [Full Text] [Related]  

  • 6. Azathioprine can be safely stopped in triple drug induction protocols including cyclosporine and steroids in renal transplantation.
    Pallardó LM; Sánchez J; Sánchez P; García J; Orero E; Beneyto I; Ros F
    Transplant Proc; 1992 Dec; 24(6):2604-5. PubMed ID: 1465880
    [No Abstract]   [Full Text] [Related]  

  • 7. Analysis of risk factors affecting the outcome of primary living donor renal transplantation in Korea.
    Park K; Kim YS; Kim SI
    Transplant Proc; 1992 Dec; 24(6):2426-7. PubMed ID: 1465816
    [No Abstract]   [Full Text] [Related]  

  • 8. Low-dose triple immunosuppression for HLA identical sibling kidney transplants.
    Schweizer RT; Roper L; Hull D; Bartus SA
    Transplant Proc; 1992 Dec; 24(6):2609. PubMed ID: 1465882
    [No Abstract]   [Full Text] [Related]  

  • 9. Influence of HLA matching on the outcome of kidney transplants in a single center analysis.
    Schanz D; Blümke M; Keller E; Tanzi-Fetta RF; Kirste G
    Transplant Proc; 1992 Dec; 24(6):2455. PubMed ID: 1465828
    [No Abstract]   [Full Text] [Related]  

  • 10. Negative crossmatch on current sera and good HLA matching are the main requirements for renal transplantation in highly sensitized patients.
    Cristol JP; Mourad G; Argiles A; Seignalet J; Iborra F; Ramounau-Pigot A; Chong G; Mion C
    Transplant Proc; 1992 Dec; 24(6):2470-1. PubMed ID: 1465835
    [No Abstract]   [Full Text] [Related]  

  • 11. Influence of HLA antigens of renal transplant recipients on graft survival.
    Alamartine E; Berthoux F; Acquart S; Lepetit JC
    Transplant Proc; 1992 Dec; 24(6):2461-2. PubMed ID: 1465831
    [No Abstract]   [Full Text] [Related]  

  • 12. Single center experience with the CTS-HIT allocation system for highly immunized patients. The Leuven Collaborative Group for Transplantation.
    Roels L; Vanrenterghem Y; Waer M; Dendievel J; Emonds MP; Christiaens R; Gruwez J; Michielsen P
    Transplant Proc; 1992 Dec; 24(6):2492-3. PubMed ID: 1465841
    [No Abstract]   [Full Text] [Related]  

  • 13. Influence of recipient's HLA type on the outcome of renal transplantation.
    Forsberg B; Ekberg H; Johnson U
    Transplant Proc; 1992 Dec; 24(6):2463-5. PubMed ID: 1465832
    [No Abstract]   [Full Text] [Related]  

  • 14. Elective cyclosporine withdrawal in renal transplant recipients maintained on triple therapy.
    Keitel E; Bittar AE; Losekann A; Deboni L; Ceretta F; Goldani JC; Garcia VD
    Transplant Proc; 1992 Dec; 24(6):2606-8. PubMed ID: 1465881
    [No Abstract]   [Full Text] [Related]  

  • 15. Importance of certain HLA-A,B haplotypes for the survival of renal grafts from living-related donors.
    Polymenidis Z; Adam K; Parapanissiou E; Sakellariou G; Papakyriazi E; Antoniadis A; Papadimitriou M
    Transplant Proc; 1992 Dec; 24(6):2458-60. PubMed ID: 1465830
    [No Abstract]   [Full Text] [Related]  

  • 16. The graft survival curve: ideology and rhetoric.
    Guttmann RD
    Transplant Proc; 1992 Dec; 24(6):2407-10. PubMed ID: 1465810
    [No Abstract]   [Full Text] [Related]  

  • 17. DR6 compatibility and kidney graft survival.
    Correia AM; de Costa AG; Reis P; Rego F; Sampaio MJ; Caetano JM; Pena JR
    Transplant Proc; 1992 Dec; 24(6):2472. PubMed ID: 1465836
    [No Abstract]   [Full Text] [Related]  

  • 18. Beneficial effect of DR matching on cadaveric renal graft survival in Scandiatransplant.
    Leivestad T; Berger L; Thorsby E
    Transplant Proc; 1992 Dec; 24(6):2447-8. PubMed ID: 1465824
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of anti-HLA and anti-idiotypic antibodies on the long-term survival of heart and kidney allografts.
    Reed E; Cohen DJ; Barr ML; Ho E; Marboe CC; Rose EA; Hardy M; Suciu-Foca N
    Transplant Proc; 1992 Dec; 24(6):2494-5. PubMed ID: 1465842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kidney transplantation at extremes of age: CsA eliminates the increased risk in recipients < or = 5 or > or = 55 years.
    MacDonell RC; Van Buren DH; Richie RE; Johnson HK; Nylander WA; Helderman JH; Ynares CM; Trusler LA; Green WF; Crowe DA
    Transplant Proc; 1994 Oct; 26(5):2518-21. PubMed ID: 7940774
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.